{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:28:49Z","timestamp":1786998529005,"version":"build-2736575974"},"reference-count":78,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["705952"],"award-info":[{"award-number":["705952"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["INI-147824"],"award-info":[{"award-number":["INI-147824"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["TFF-122868"],"award-info":[{"award-number":["TFF-122868"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012273","name":"Lotte and John Hecht Memorial Foundation","doi-asserted-by":"publisher","award":["703014"],"award-info":[{"award-number":["703014"]}],"id":[{"id":"10.13039\/100012273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymthe.2023.09.017","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T02:26:36Z","timestamp":1695781596000},"page":"3176-3192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSV\u039451 oncolytic virotherapy"],"prefix":"10.1016","volume":"31","author":[{"given":"Boaz","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glib","family":"Maznyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jirovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsimrat K.","family":"Birdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akram","family":"Alwithenani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Lorimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Vanderhyden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozanne","family":"Arulanandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4862-2795","authenticated-orcid":false,"given":"Jean-Simon","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.09.017_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-016-0158-5","article-title":"Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy","volume":"4","author":"Rehman","year":"2016","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2023.09.017_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2023.09.017_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2023.09.017_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fonc.2014.00191","article-title":"Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses","volume":"4","author":"Forbes","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/sj.icb.7100159","article-title":"Interferon type I responses in primary and secondary infections","volume":"86","author":"Alsharifi","year":"2008","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib6","doi-asserted-by":"crossref","first-page":"e2008","DOI":"10.1002\/rmv.2008","article-title":"Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses","volume":"28","author":"Matveeva","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/srep02375","article-title":"Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy","volume":"3","author":"Liu","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.09.017_bib8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/mt.2010.67","article-title":"A High-throughput Pharmacoviral Approach Identifies Novel Oncolytic Virus Sensitizers","volume":"18","author":"Diallo","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.09.017_bib9","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/ncomms7410","article-title":"Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing","volume":"6","author":"Arulanandam","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.09.017_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1613","article-title":"Dimethyl fumarate potentiates oncolytic virotherapy through NF-\u03baB inhibition","volume":"10","author":"Selman","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.09.017_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymthe.2017.10.014","article-title":"Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds","volume":"26","author":"Selman","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.09.017_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib13","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/13543784.2012.707192","article-title":"MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy","volume":"21","author":"Nawrocki","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ymthe.2023.09.017_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-019-0979-1","article-title":"Neddylation: a novel modulator of the tumor microenvironment","volume":"18","author":"Zhou","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2023.09.017_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrm3919","article-title":"Protein neddylation: beyond cullin\u2013RING ligases","volume":"16","author":"Enchev","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib16","article-title":"Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells. Gires O, editor","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2023.09.017_bib17","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1007\/s00018-009-8712-7","article-title":"Regulation of cullin-RING E3 ubiquitin-ligases by neddylation and dimerization","volume":"66","author":"Merlet","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2023.09.017_bib18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.09.017_bib19","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1038\/s41598-017-06098-y","article-title":"MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma","volume":"7","author":"Tong","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.09.017_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/15384047.2014.1003003","article-title":"Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells","volume":"16","author":"Wang","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2023.09.017_bib21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","article-title":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML","volume":"131","author":"Swords","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.09.017_bib22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1078-0432.CCR-15-1338","article-title":"Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924\/MLN4924) in Patients with Advanced Solid Tumors","volume":"22","author":"Sarantopoulos","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.09.017_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.omto.2022.04.004","article-title":"Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy","volume":"25","author":"Wong","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2023.09.017_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2014.10.026","article-title":"Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus","volume":"474","author":"Felt","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2023.09.017_bib25","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1128\/JVI.79.7.4170-4179.2005","article-title":"Vesicular Stomatitis Viruses Expressing Wild-Type or Mutant M Proteins Activate Apoptosis through Distinct Pathways","volume":"79","author":"Gaddy","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-immunol-030409-101323","article-title":"HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection","volume":"29","author":"Andersson","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1471-2105-10-48","article-title":"GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists","volume":"10","author":"Eden","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ymthe.2023.09.017_bib28","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1371\/journal.pcbi.0030039","article-title":"Discovering Motifs in Ranked Lists of DNA Sequences. Fraenkel E, editor","volume":"3","author":"Eden","year":"2007","journal-title":"Plos Comput. Biol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/onc.2015.104","article-title":"The NEDD8 inhibitor MLN4924 increases the size of the nucleolus and activates p53 through the ribosomal-Mdm2 pathway","volume":"35","author":"Bailly","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2023.09.017_bib30","doi-asserted-by":"crossref","first-page":"10310","DOI":"10.1158\/0008-5472.CAN-10-2062","article-title":"NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells","volume":"70","author":"Lin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.09.017_bib31","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.09.017_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq149","article-title":"Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data","volume":"38","author":"Essaghir","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2023.09.017_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib34","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-13-0987","article-title":"The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-\u03baB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells","volume":"20","author":"Godbersen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.09.017_bib35","doi-asserted-by":"crossref","first-page":"35756","DOI":"10.1074\/jbc.M112.397703","article-title":"Inhibition of Neddylation Represses Lipopolysaccharide-induced Proinflammatory Cytokine Production in Macrophage Cells","volume":"287","author":"Chang","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2023.09.017_bib36","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.4049\/jimmunol.1501752","article-title":"MLN4924, a First-in-Class NEDD8-Activating Enzyme Inhibitor, Attenuates IFN-\u03b2 Production","volume":"196","author":"Song","year":"2016","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.09.017_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.virol.2012.11.014","article-title":"Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling","volume":"436","author":"Moerdyk-Schauwecker","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2023.09.017_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12943-022-01664-z","article-title":"Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2023.09.017_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/srep26786","article-title":"First-in-class small molecule potentiators of cancer virotherapy","volume":"6","author":"Dornan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.09.017_bib42","doi-asserted-by":"crossref","first-page":"TPS7077","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7077","article-title":"Phase 3 study of first line pevonedistat (PEV)\u00a0+ azacitidine (AZA) versus single-agent AZA in patients with higher-risk myelodysplastic syndromes (HR MDS), chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (AML)","volume":"36","author":"Sekeres","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib43","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jha2.2","article-title":"Pevonedistat, a NEDD8-activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre-clinical models of diffuse large B-cell lymphoma","volume":"1","author":"Torka","year":"2020","journal-title":"eJHaem"},{"key":"10.1016\/j.ymthe.2023.09.017_bib44","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1182\/blood-2015-04-640920","article-title":"Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in\u00a0vivo","volume":"127","author":"Czuczman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2023.09.017_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10637-016-0398-8","article-title":"Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)","volume":"35","author":"Wong","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ymthe.2023.09.017_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004771","article-title":"NEDDylation Is Essential for Kaposi\u2019s Sarcoma-Associated Herpesvirus Latency and Lytic Reactivation and Represents a Novel Anti-KSHV Target. Fr\u00fch K, editor","volume":"11","author":"Hughes","year":"2015","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2023.09.017_bib47","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1111\/febs.15584","article-title":"Diverse and pivotal roles of neddylation in metabolism and immunity","volume":"288","author":"Zou","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.ymthe.2023.09.017_bib48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12977-015-0192-2","article-title":"HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins","volume":"12","author":"Ramirez","year":"2015","journal-title":"Retrovirology"},{"key":"10.1016\/j.ymthe.2023.09.017_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/srep19977","article-title":"Broad and potent antiviral activity of the NAE inhibitor MLN4924","volume":"6","author":"Le-Trilling","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.09.017_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2017.11.004","article-title":"Inhibition of neddylation pathway represses influenza virus replication and pro-inflammatory responses","volume":"514","author":"Sun","year":"2018","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2023.09.017_bib51","article-title":"NEDDylation of PB2 Reduces Its Stability and Blocks the Replication of Influenza A Virus","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2023.09.017_bib52","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1128\/JVI.74.7.3366-3378.2000","article-title":"Alpha\/Beta Interferon Protects Adult Mice from Fatal Sindbis Virus Infection and Is an Important Determinant of Cell and Tissue Tropism","volume":"74","author":"Ryman","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000361","article-title":"Functional Crosstalk between Type I and II Interferon through the Regulated Expression of STAT1","volume":"8","author":"Gough","year":"2010","journal-title":"Plos Biol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib54","doi-asserted-by":"crossref","first-page":"28779","DOI":"10.1074\/jbc.272.45.28779","article-title":"Interferon-resistant Human Melanoma Cells Are Deficient in ISGF3 Components, STAT1, STAT2, and p48-ISGF3\u03b3","volume":"272","author":"Wong","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2023.09.017_bib55","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0092-8674(00)81288-X","article-title":"Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK\u2013STAT Signaling Pathway","volume":"84","author":"Meraz","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2023.09.017_bib56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0092-8674(00)81289-1","article-title":"Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease","volume":"84","author":"Durbin","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2023.09.017_bib57","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1084\/jem.20060792","article-title":"Essential role of IPS-1 in innate immune responses against RNA viruses","volume":"203","author":"Kumar","year":"2006","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2023.09.017_bib58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1097-2765(00)80013-1","article-title":"The Mechanism of Transcriptional Synergy of an In\u00a0Vitro Assembled Interferon-\u03b2 Enhanceosome","volume":"1","author":"Kim","year":"1997","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ymthe.2023.09.017_bib59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1101\/sqb.1999.64.149","article-title":"The IFN- Enhancer: A Paradigm for Understanding Activation and Repression of Inducible Gene Expression","volume":"64","author":"Munshi","year":"1999","journal-title":"Cold Spring Harb. Symp. Quant. Biol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib60","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.virol.2016.09.009","article-title":"The vesicular stomatitis virus matrix protein inhibits NF-\u03baB activation in mouse L929 cells","volume":"499","author":"Varble","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2023.09.017_bib61","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1091\/mbc.e16-05-0273","article-title":"Perturbation of neddylation-dependent NF-\u03baB responses in the intestinal epithelium drives apoptosis and inhibits resolution of mucosal inflammation. Yap A","volume":"27","author":"Ehrentraut","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ymthe.2023.09.017_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009901","article-title":"Myeloid neddylation targets IRF7 and promotes host innate immunity against RNA viruses. Li K, editor","volume":"17","author":"Zhao","year":"2021","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2023.09.017_bib63","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.exphem.2013.09.005","article-title":"Oncolytic vesicular stomatitis virus and bortezomib are antagonistic against myeloma cells in\u00a0vitro but have additive anti-myeloma activity in\u00a0vivo","volume":"41","author":"Yarde","year":"2013","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib64","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.virol.2015.08.003","article-title":"Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1","volume":"485","author":"Cataldi","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2023.09.017_bib65","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1089\/jir.2012.0002","article-title":"Inhibition of Type I Interferon-Mediated Antiviral Action in Human Glioma Cells by the IKK Inhibitors BMS-345541 and TPCA-1","volume":"32","author":"Du","year":"2012","journal-title":"J.\u00a0Interferon Cytokine Res."},{"key":"10.1016\/j.ymthe.2023.09.017_bib66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bbmt.2016.10.022","article-title":"Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice","volume":"23","author":"Pai","year":"2017","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.ymthe.2023.09.017_bib67","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib68","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","article-title":"Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors","volume":"17","author":"Cervera-Carrascon","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2023.09.017_bib69","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3390\/biomedicines9040419","article-title":"Oncolytic Virotherapy for Cancer: Clinical Experience","volume":"9","author":"Chaurasiya","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2023.09.017_bib70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib71","doi-asserted-by":"crossref","first-page":"25704","DOI":"10.1074\/jbc.M109.023846","article-title":"The Development of a Metabolic Disease Phenotype in CTP:Phosphoethanolamine Cytidylyltransferase-deficient Mice","volume":"284","author":"Fullerton","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2023.09.017_bib72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-61779-340-0_10","article-title":"Propagation, Purification, and In\u00a0Vivo Testing of Oncolytic Vesicular Stomatitis Virus Strains","volume":"797","author":"Diallo","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib73","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/mt.2010.264","article-title":"Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy","volume":"19","author":"Sobol","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.09.017_bib74","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.09.017_bib75","doi-asserted-by":"crossref","DOI":"10.3791\/51890-v","article-title":"High-throughput Titration of Luciferase-expressing Recombinant Viruses","author":"Garcia","year":"2014","journal-title":"J.\u00a0Vis. Exp."},{"key":"10.1016\/j.ymthe.2023.09.017_bib76","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.09.017_bib77","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2023.09.017_bib78","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nmeth.4324","article-title":"Differential analysis of RNA-seq incorporating quantification uncertainty","volume":"14","author":"Pimentel","year":"2017","journal-title":"Nat. Methods"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162300504X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162300504X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:10:27Z","timestamp":1761502227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162300504X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":78,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S152500162300504X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSV\u039451 oncolytic virotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023","name":"copyright","label":"Copyright"}]}}